Who can use Koselugo(Selumetinib)?

Selumetinib is an oral small-molecule kinase inhibitor and a selective inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2).

Who can use Koselugo(Selumetinib)?

By inhibiting the activity of MEK1/2 proteins, it blocks the RAS/RAF/MEK/ERK signaling pathway, thereby suppressing tumor cell proliferation and survival.

Selumetinib is primarily indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1). It can significantly reduce tumor volume and improve related clinical symptoms.

Related Columns

Selumetinib(Koselugo)

KOSELUGO (selumetinib) is indicated for the treatment of pediatric patients...

WeChat Scan
Free Inquiry

What is Selumetinib (Koselugo)?

Selumetinib (Koselugo) is a kinase inhibitor primarily used for the treatment of specific types of nervous system tumors. As a targeted therapy drug, its unique pharmacological effects provide an impo...

What is Selumetinib (Koselugo)?

Selumetinib (Koselugo) is a targeted therapeutic drug for diseases caused by specific gene mutations. Developed by AstraZeneca, it was first approved for marketing by the U.S. FDA in 2020.What is Selu...

Is Selumetinib a targeted drug?

Selumetinib is a targeted therapy that specifically targets specific genetic mutations, primarily for the treatment of plexiform neurofibromas associated with neurofibromatosis type 1. This artic...

What kind of drug is Selumetinib?

Selumetinib is a targeted therapy that specifically targets specific types of neurofibromatosis. This article will introduce the basic information, dosage, and precautions of Selumetinib in ...

What diseases is Selumetinib treating?

Selumetinib is a targeted therapy drug that is primarily used to treat specific types of neurofibromatosis. This article will provide a detailed description of who Selumetinib can be treated...